Evidence map›Paper›PMID 33540417›Full record

ReviewNephron2021

Dose of Continuous Renal Replacement Therapy in Critically Ill Patients: A Bona Fide Quality Indicator.

Enzo Vásquez Jiménez, Samaya J Anumudu, Javier A Neyra

Open access · bronzeAbstract readReview
In one paragraph

Review in Nephron, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Enzo Vásquez JiménezDepartment of Nephrology, National Institute of Cardiology Mexico, Mexico City, Mexico.
Samaya J AnumuduDivision of Nephrology, Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.
Javier A NeyraDivision of Nephrology, Department of Internal Medicine, Bone and Mineral Metabolism, University of Kentucky, Lexington, Kentucky, USA, javier.neyra@uky.edu.
Baylor College of Medicine · USInstituto Nacional de Cardiología · MXUniversity of Kentucky · US

Funding

UAB-UCSD O'Brien Core Center for Acute Kidney Injury ResearchP30DK079337 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SANDERS, PAUL W. · 2008 to 2022
$18.3M
Blood and Urine Biomarkers for Predicting Long-Term Adverse Kidney and Cardiovascular Outcomes after Cardiac SurgeryR01HL148448 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI FOX, AMANDA A · 2019 to 2023
$3.7M
Artificial Intelligence to Predict Outcomes in Patients with Acute Kidney Injury on Continuous Renal Replacement TherapyR01DK133539 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Girish Nitin Nadkarni, Javier A. Neyra · 2023 to 2026
$2.6M
Risk Clustering and Stratification in Genetically High-Risk Individuals Using Electronic Medical Records and BiomarkersK23DK107908 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI NADKARNI, GIRISH NITIN · 2016 to 2020
$930k
Association of baseline and time-varying serum magnesium levels with cardiovascular disease events in SPRINT participants with and without chronic kidney diseaseR21HL145424 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2019 to 2020
$257k
Artificial Intelligence to Predict Outcomes in Patients with Acute Kidney Injury on Continuous Renal Replacement TherapyR56DK126930 · NIDDK · UNIVERSITY OF KENTUCKY · PI NADKARNI, GIRISH NITIN, NEYRA, JAVIER A. · 2020 to 2020
$100k
NHLBI NIH HHS R01 HL148448NHLBI NIH HHS R21 HL145424NIDDK NIH HHS K23 DK107908NIDDK NIH HHS P30 DK079337NIDDK NIH HHS R01 DK133539NIDDK NIH HHS R56 DK126930
6 · The paper itself

Abstract

Acute kidney injury (AKI) is common in critically ill patients, and renal replacement therapy (RRT) constitutes an important aspect of acute management during critical illness. Continuous RRT (CRRT) is frequently utilized in intensive care unit settings, particularly in patients with severe AKI, fluid overload, and hemodynamic instability. The main goal of CRRT is to timely optimize solute control, acid-base, and volume status. Total effluent dose of CRRT is a deliverable that depends on multiple factors and therefore should be systematically monitored (prescribed vs. delivered) and iteratively adjusted in a sustainable mode. In this manuscript, we review current evidence of CRRT dosing and provide recommendations for its implementation as a quality indicator of CRRT delivery.

Indexed as

Critical IllnessQuality Indicators, Health CareAcid-Base EquilibriumAcute Kidney InjuryHumansRenal Replacement TherapyAcute kidney injuryContinuous renal replacement therapyDoseQuality indicatorQuality metric

Identifiers

PMID33540417
PMCPMC7965247
OpenAlexW3127374965

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.